{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:41Z","timestamp":1791404561912,"version":"4.3.3"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.1001\/jamaneurol.2019.2050","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T15:33:04Z","timestamp":1563809584000},"page":"1219","source":"Crossref","is-referenced-by-count":141,"title":["Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease"],"prefix":"10.1001","volume":"76","author":[{"given":"Christopher H.","family":"van Dyck","sequence":"first","affiliation":[{"name":"Alzheimer\u2019s Disease Research Unit, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haakon B.","family":"Nygaard","sequence":"additional","affiliation":[{"name":"Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Chen","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Donohue","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rema","family":"Raman","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California, San Diego"},{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Brewer","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of California, San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Koeppe","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany W.","family":"Chow","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon","family":"Gessert","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Gale","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Reiman","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Strittmatter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi190053r1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.biopsych.2017.08.001","article-title":"Modulation of ?- and \u00df-secretases as early prevention against Alzheimer\u2019s disease.","volume":"83","author":"Voytyuk","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"4","key":"noi190053r2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u00df monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise.","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"5","key":"noi190053r3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nn.2100","article-title":"Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism.","volume":"11","author":"Berman","year":"2008","journal-title":"Nat Neurosci"},{"issue":"1","key":"noi190053r4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nn1372","article-title":"Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.","volume":"8","author":"Cleary","year":"2005","journal-title":"Nat Neurosci"},{"issue":"6286","key":"noi190053r5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","article-title":"Complement and microglia mediate early synapse loss in Alzheimer mouse models.","volume":"352","author":"Hong","year":"2016","journal-title":"Science"},{"issue":"4","key":"noi190053r6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"A\u00df oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease.","volume":"27","author":"Lacor","year":"2007","journal-title":"J Neurosci"},{"issue":"11","key":"noi190053r7","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from A\u00df1-42 are potent central nervous system neurotoxins.","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7233","key":"noi190053r8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nature07761","article-title":"Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.","volume":"457","author":"Laur\u00e9n","year":"2009","journal-title":"Nature"},{"issue":"7082","key":"noi190053r9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-beta protein assembly in the brain impairs memory.","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nature"},{"issue":"6","key":"noi190053r10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neuron.2009.05.012","article-title":"Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake.","volume":"62","author":"Li","year":"2009","journal-title":"Neuron"},{"issue":"7","key":"noi190053r11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nn.2583","article-title":"Amyloid-beta-induced neuronal dysfunction in Alzheimer\u2019s disease: from synapses toward neural networks.","volume":"13","author":"Palop","year":"2010","journal-title":"Nat Neurosci"},{"issue":"8","key":"noi190053r12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory.","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"issue":"6880","key":"noi190053r13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"issue":"4","key":"noi190053r14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.biopsych.2017.11.020","article-title":"Prion protein as a toxic acceptor of amyloid-\u00df oligomers.","volume":"83","author":"Purro","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"pt 2","key":"noi190053r15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/brain\/awv356","article-title":"Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer\u2019s disease.","volume":"139","author":"Haas","year":"2016","journal-title":"Brain"},{"issue":"5","key":"noi190053r16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","article-title":"Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer a\u00df oligomer bound to cellular prion protein.","volume":"79","author":"Um","year":"2013","journal-title":"Neuron"},{"issue":"47","key":"noi190053r17","doi-asserted-by":"publisher","first-page":"16857","DOI":"10.1523\/JNEUROSCI.1858-12.2012","article-title":"The complex PrP(c)-fyn couples human oligomeric A\u00df with pathological tau changes in Alzheimer\u2019s disease.","volume":"32","author":"Larson","year":"2012","journal-title":"J Neurosci"},{"issue":"9","key":"noi190053r18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/nn.3178","article-title":"Alzheimer amyloid-\u00df oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.","volume":"15","author":"Um","year":"2012","journal-title":"Nat Neurosci"},{"issue":"9","key":"noi190053r19","doi-asserted-by":"publisher","first-page":"e1004606","DOI":"10.1371\/journal.pgen.1004606","article-title":"Genome-wide association meta-analysis of neuropathologic features of Alzheimer\u2019s disease and related dementias.","volume":"10","author":"Beecham","year":"2014","journal-title":"PLoS Genet"},{"issue":"6","key":"noi190053r20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1365-2990.2010.01103.x","article-title":"Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy.","volume":"36","author":"Bhaskar","year":"2010","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"42","key":"noi190053r21","doi-asserted-by":"publisher","first-page":"35119","DOI":"10.1074\/jbc.M505895200","article-title":"Disease-related modifications in tau affect the interaction between fyn and tau.","volume":"280","author":"Bhaskar","year":"2005","journal-title":"J Biol Chem"},{"issue":"42","key":"noi190053r22","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.1523\/JNEUROSCI.2980-05.2005","article-title":"Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer\u2019s disease.","volume":"25","author":"Chin","year":"2005","journal-title":"J Neurosci"},{"issue":"19","key":"noi190053r23","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1523\/JNEUROSCI.0277-04.2004","article-title":"Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice.","volume":"24","author":"Chin","year":"2004","journal-title":"J Neurosci"},{"issue":"6","key":"noi190053r24","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/mp.2016.59","article-title":"Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of tau pathology.","volume":"22","author":"Dourlen","year":"2017","journal-title":"Mol Psychiatry"},{"issue":"33","key":"noi190053r25","doi-asserted-by":"publisher","first-page":"17112","DOI":"10.1074\/jbc.M116.720664","article-title":"Oligomers of amyloid \u00df prevent physiological activation of the cellular prion protein-metabotropic glutamate receptor 5 complex by glutamate in Alzheimer disease.","volume":"291","author":"Haas","year":"2016","journal-title":"J Biol Chem"},{"issue":"3","key":"noi190053r26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models.","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"issue":"6","key":"noi190053r27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ana.24394","article-title":"Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.","volume":"77","author":"Kaufman","year":"2015","journal-title":"Ann Neurol"},{"issue":"12","key":"noi190053r28","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease.","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat Genet"},{"issue":"pt 21","key":"noi190053r29","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1242\/jcs.111.21.3167","article-title":"Tau interacts with src-family non-receptor tyrosine kinases.","volume":"111","author":"Lee","year":"1998","journal-title":"J Cell Sci"},{"issue":"9","key":"noi190053r30","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1523\/JNEUROSCI.4162-03.2004","article-title":"Phosphorylation of tau by fyn: implications for Alzheimer\u2019s disease.","volume":"24","author":"Lee","year":"2004","journal-title":"J Neurosci"},{"issue":"2","key":"noi190053r31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1523\/JNEUROSCI.4152-10.2011","article-title":"Amyloid-\u00df\/fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer\u2019s disease.","volume":"31","author":"Roberson","year":"2011","journal-title":"J Neurosci"},{"issue":"4","key":"noi190053r32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","article-title":"Targeting fyn kinase in Alzheimer\u2019s disease.","volume":"83","author":"Nygaard","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"1","key":"noi190053r33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/alzrt238","article-title":"Fyn kinase inhibition as a novel therapy for Alzheimer\u2019s disease.","volume":"6","author":"Nygaard","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"noi190053r35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/WAD.0b013e31819cd4be","article-title":"Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil.","volume":"23","author":"Jones","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"7","key":"noi190053r36","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"5","key":"noi190053r37","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","article-title":"Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer\u2019s disease treatment studies.","volume":"159","author":"Alexander","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"6","key":"noi190053r38","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1073\/pnas.061509598","article-title":"Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer\u2019s disease.","volume":"98","author":"Reiman","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"noi190053r39","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.neuroimage.2010.02.064","article-title":"Twelve-month metabolic declines in probable Alzheimer\u2019s disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer\u2019s Disease Neuroimaging Initiative.","volume":"51","author":"Chen","year":"2010","journal-title":"Neuroimage"},{"issue":"3","key":"noi190053r40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"5","key":"noi190053r41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/(ISSN)1531-8249","article-title":"Pathological verification of ischemic score in differentiation of dementias.","volume":"7","author":"Rosen","year":"1980","journal-title":"Ann Neurol"},{"issue":"3","key":"noi190053r43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: A practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"19","key":"noi190053r44","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1158\/1078-0432.CCR-10-0748","article-title":"Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.","volume":"16","author":"Baselga","year":"2010","journal-title":"Clin Cancer Res"},{"key":"noi190053r46","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope.","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"11","key":"noi190053r47","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease.","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"noi190053r48","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease.","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"11","key":"noi190053r49","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules.","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"12","key":"noi190053r50","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"5","key":"noi190053r51","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","article-title":"The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.","volume":"48","author":"Cummings","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"noi190053r52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.media.2011.02.005","article-title":"Nonlinear registration of longitudinal images and measurement of change in regions of interest.","volume":"15","author":"Holland","year":"2011","journal-title":"Med Image Anal"},{"issue":"3","key":"noi190053r53","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","article-title":"An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest.","volume":"31","author":"Desikan","year":"2006","journal-title":"Neuroimage"},{"issue":"1","key":"noi190053r54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","article-title":"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease.","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"noi190053r34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/acprof:oso\/9780195328875.003.0020","volume-title":"Imaging the Aging Brain","author":"Reiman","year":"2009"},{"key":"noi190053r42","first-page":"165","volume-title":"Clinical Gerontology: A Guide to Assessment and Intervention","author":"Sheikh","year":"1986"},{"key":"noi190053r45","author":"Chen"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2737805\/jamaneurology_van_dyck_2019_oi_190053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T10:21:46Z","timestamp":1664014906000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2737805"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.2050","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}